Objective
An optimal immunotherapeutic regimen will be established and its efficacy evaluated in HIV-infected individuals. The proposal comprises the improvement of an adjuvant protein HIV vaccine for therapeutic use that has proved efficacious in a stringent rhesus monkey SHIV challenge rode. The irnprovement will be achieved through combination of the adjuvant protein vaccine with particle-mediated immune delivery of DNA in prime-boost immunization regimen. This regimen will be investigated in mice and rhesus monkeys for superior immunogenicity and efficacy. One or several prime-boost immunization regimen will be evaluated in initial phase I clinical trials in exonerative volunteers. If the prime-boost combinations are immunogenic, the best combination will be tested for its efficacy in a therapeutic trial in HIV-Positive patients.
Fields of science
- medical and health sciencesbasic medicineimmunologyimmunisation
- natural sciencesbiological sciencesgeneticsDNA
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
--- RIXENSART
Belgium